AQP4 (p = 1.81e − 06), CLDN18 (p = 4.64e − 06), FOXA2 (p = 1.28e − 04), NKX2-1(p = 7.56e − 04), PGC (p = 3.08e − 07),SFTPB (p = 3.33e − 07), SFTPC (p = 1.4e − 08), and SFTPD (p = 1.54e − 07) show that the AT II-associated genes were inclined to high expression in NSCLC patients with advanced cancer stages (Figure 3). This evidence concerns the gene SFTPC and cancer.